GLP-1 and Muscle Loss: What the Meta-Analysis Findings Mean

A comprehensive meta-analysis quantifies the lean mass loss associated with GLP-1 therapy and what it means for long-term health.

The Lean Mass Problem

Weight loss from GLP-1 therapy is not purely fat loss — approximately 25-40% of total weight lost is lean body mass. This finding, confirmed across multiple trials, has raised concerns about sarcopenia (muscle loss), particularly in older adults. The meta-analysis pooled data from major trials including STEP, SURPASS, and TRIUMPH programs to provide the most precise estimate yet of this effect.

Quantifying the Loss

The meta-analysis found that GLP-1 therapy results in an average lean mass reduction of 5-8 kg over 12-18 months of treatment. This is approximately 25-35% of total weight loss. The loss appears to be dose-dependent and more pronounced with higher percentages of total weight loss. DXA scans and bioimpedance data consistently show reductions in both skeletal muscle mass and appendicular lean mass.

Mitigation Strategies

Resistance training is the most effective intervention for preserving muscle during GLP-1 therapy. Adequate protein intake (1.2-1.6 g/kg/day), creatine supplementation, and maintaining physical activity levels are also important. Some practitioners are now exploring combining GLP-1 therapy with anabolic agents or MOTS-c to counteract muscle loss.

Important Disclaimer

This article is for educational and research purposes only. Peptides discussed may not be FDA-approved for all uses described. Always consult with a qualified healthcare provider before starting any peptide protocol. The information provided here is synthesized from published research, clinical trial data, and community discussions.

Keywords: GLP-1, muscle loss, lean mass, sarcopenia, meta analysis

Sources: Published research papers, clinical trial databases, community discussions, peptiq.io educational content